Disclosed
26/10/27 09:08
Company
Sumitomo Pharma Co., Ltd.
Industry
Pharmaceutical
Category
Other
Title
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R-R KMT2A-Rearranged Acute Leuke